Arsenic Trioxide

證據等級: L5

預測適應症: 10 個

Arsenic Trioxide: From Acute Promyelocytic Leukemia to Myelodysplastic Syndrome

One-Sentence Summary

Arsenic trioxide (ATO) is a globally established antineoplastic agent best known for achieving >80% complete remission in relapsed Acute Promyelocytic Leukemia (APL), though it currently holds no New Zealand marketing authorization. The TxGNN model predicts it may be effective for Myelodysplastic Syndrome (MDS) — the top-ranked prediction specifically targets unclassified MDS (score 99.93%), while the broader MDS indication (score 99.91%) is supported by 24 clinical trials and 20 publications, including a 2023 systematic review and a 2025 prospective randomized study.

Quick Overview

Item	Content
Original Indication	Acute Promyelocytic Leukemia (APL) — established global use; not registered in New Zealand
Predicted New Indication	Myelodysplastic Syndrome (MDS)
TxGNN Prediction Score	99.91% (MDS); top-ranked prediction: Unclassified MDS at 99.93%
Evidence Level	L2
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on established pharmacology, arsenic trioxide is best characterized as a multi-target antineoplastic metalloid agent. In APL, ATO degrades the PML-RARα fusion oncoprotein through oxidative modification of its cysteine residues followed by proteasomal degradation, triggering terminal differentiation and apoptosis of leukemic blasts. This confirms ATO's capacity to selectively eliminate clonal bone marrow cells with aberrant myeloid differentiation — a hallmark equally central to MDS pathology.

APL and MDS are both clonal bone marrow disorders arising from dysregulated myeloid precursors. The mechanistic bridge from APL to MDS is supported by four complementary pathways: (1) ROS-mediated mitochondrial apoptosis (cytochrome-c / caspase-9/-3 cascade) that selectively purges dysplastic clonal progenitors; (2) inhibition of NF-κB and anti-apoptotic proteins BCL2/BCL-XL, which are upregulated in MDS marrow as shown in the Blood 2005 study (PMID 16105982); (3) downregulation of DNMT enzymatic activity, enabling synergistic demethylation when combined with hypomethylating agents such as decitabine; and (4) immunomodulatory expansion of CD4+CD25+Foxp3+ regulatory T cells that help restore immune homeostasis in the disordered marrow microenvironment.

A 2023 systematic review and component network meta-analysis (PMID 37908176) provided the first rigorous quantitative synthesis of ATO-containing regimens across MDS subtypes, and a 2025 prospective randomized study (PMID 40167011) confirmed superior outcomes with the decitabine+ATO combination over decitabine alone in elderly high-risk MDS patients. The TxGNN model's highest-scoring prediction specifically identifies unclassified MDS (TxGNN rank 929, score 99.93%) — a subtype where dedicated clinical trial data remain absent — but the mechanistic rationale and the substantial evidence base for MDS broadly make this prediction highly plausible.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06778187	Phase 2	Recruiting	30	Oral ATO (Arsenol®) + ascorbic acid ± investigator-choice low-intensity therapy in untreated or R/R TP53-mutated MDS, AML, and CMML; the most current frontline MDS-specific ATO trial (started February 2025)
NCT02190695	Phase 2	Completed	92	Three-arm randomized study: decitabine vs. decitabine+carboplatin vs. decitabine+ATO in R/R and elderly AML/MDS; directly evaluates ATO combination efficacy and safety in MDS
NCT00454480	Phase 2/3	Completed	2,000	Large-scale treatment development programme for elderly AML and high-risk MDS; provides extensive safety and efficacy background data including MDS subgroup
NCT06670222	Phase 1	Recruiting	24	Dose-escalation oral ATO in low-risk MDS failing erythropoiesis-stimulating agents and luspatercept; evaluates emerging oral formulation in a treatment-refractory population (starting July 2025)
NCT00671697	Phase 1	Completed	13	Decitabine + ATO + ascorbic acid triple combination in MDS and AML; establishes combination dosing safety data supporting the hypomethylating agent + ATO approach
NCT00195104	Phase 1/2	Completed	87	ATO + low-dose cytarabine in intermediate-2 / high-risk MDS and poor-prognosis AML; complete remission achieved in 17%, including patients with unfavorable cytogenetics
NCT00093366	Phase 1/2	Completed	32	ATO + etanercept (TNF-α inhibitor) in advanced-stage MDS; explores immunomodulatory combination approach targeting the inflammatory marrow microenvironment
NCT00803530	Phase 2	Terminated	55	Prospective multicenter ATO + ascorbic acid in MDS; largest-enrollment ATO monotherapy-adjacent combination trial, safety data available despite early termination
NCT00225992	Phase 2	Terminated	N/A	ATO monotherapy in MDS using a loading-dose regimen (0.30 mg/kg days 1–5 of cycle 1); primary endpoint: improvement in blood counts and reduction of transfusion dependence
NCT00274820	Phase 2	Completed	15	TADA regimen (thalidomide + ATO + dexamethasone + ascorbic acid) in chronic idiopathic myelofibrosis and MDS/MPN overlap disorders; evaluates ATO in myeloid overlap syndromes

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37908176	2023	Systematic Review / Meta-analysis	Hematology	First comprehensive network meta-analysis of ATO-containing regimens in MDS; evaluates efficacy (overall response, haematological improvement) and adverse events; identifies optimal combination strategies
40167011	2025	Prospective Randomized Study	Hematology	Decitabine+ATO demonstrates superior efficacy over decitabine alone in elderly high-risk MDS patients with acceptable toxicity; most recent prospective evidence supporting this combination
38816179	2024	Comparative Clinical Study	Immunopharmacology and Immunotoxicology	Compares immunological effects of realgar (oral arsenic disulfide) vs. IV ATO in a murine MDS model; distinguishes route-specific immune modulation relevant to emerging oral ATO formulations
30898879	2019	In vitro / Mechanistic	Journal of Investigative Medicine	Decitabine and ATO show synergistic apoptosis induction in MUTZ-1 and SKM-1 MDS cell lines via endoplasmic reticulum stress; provides cellular mechanistic basis for the combination
22964015	2012	Ex vivo Clinical / Mechanistic	Journal of Hematology & Oncology	ATO + ascorbic acid modulates expression of 93 apoptotic genes including BCL2-family members in bone marrow of MDS patients; confirms in vivo mechanistic activity
16105982	2005	In vitro / Mechanistic	Blood	NF-κB activity is elevated in high-grade MDS (RAEB) vs. low-grade (RA/RARS); ATO inhibits NF-κB and FLIP in MDS CD34+ cells, identifying key molecular targets
20956016	2011	Phase I/II Clinical	Leukemia Research	ATO + low-dose cytarabine in 49 previously untreated int-2/high-risk MDS patients: CR 17%, including patients with poor-prognosis cytogenetics; 4-week mortality 8%
31775455	2019	Retrospective Clinical Study	Zhonghua Nei Ke Za Zhi	Low-dose subcutaneous decitabine + ATO in 11 intermediate/high-risk MDS patients: CR 27%, haematological improvement 55%; median follow-up 413 days
18282365	2007	Review / Clinical Data Summary	Clinical Lymphoma & Myeloma	Comprehensive review of ATO clinical data in APL and MDS; details response rates, dosing schedules, single-agent vs. combination performance, and rationale for MDS use
15610661	2005	Clinical Review	Current Hematology Reports	Early clinical evidence establishing ATO as an MDS treatment candidate; reviews pro-apoptotic, antiproliferative, and anti-angiogenic mechanisms and early trial outcomes

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted cytotoxic (Metalloid / Arsenic-based agent); degrades PML-RARα oncoprotein in APL; induces ROS-mediated mitochondrial apoptosis and NF-κB inhibition in MDS and other haematological malignancies
Myelosuppression Risk	Low to Moderate (dose-dependent); at standard therapeutic doses, myelosuppression is less prominent than with conventional cytotoxics; differentiation syndrome / APL differentiation syndrome is the more characteristic acute toxicity in APL
Emetogenicity Classification	Low
Monitoring Items	QTc interval (12-lead ECG before initiation and twice weekly during induction), serum electrolytes (K⁺ and Mg²⁺ must be maintained ≥4.0 mEq/L and ≥1.8 mg/dL respectively), CBC with differential, liver function tests (AST/ALT), renal function (creatinine), serum arsenic levels if prolonged use
Handling Protection	Must follow cytotoxic drug handling regulations; intravenous preparation requires closed-system drug transfer device

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple Phase 1/2 clinical trials, a 2025 prospective randomized study, and a 2023 systematic review collectively provide an L2-level evidence base supporting ATO-containing regimens in MDS; the mechanistic rationale is strong and coherent, but the absence of a completed Phase 3 RCT and New Zealand marketing authorization means clinical use requires structured oversight and regulatory pathway planning.

To proceed, the following is needed:

Regulatory pathway: ATO is not marketed in New Zealand; a Medsafe special clinical trial authorisation or Named Patient Supply application is required before any clinical use
Safety data gap: Full warnings, contraindications, and DDI profile from the NZ-equivalent package insert and DrugBank must be retrieved and reviewed (Evidence Pack data gaps DG001/DG002)
Formulation decision: Clarify whether IV (standard) or oral ATO (Arsenol® — actively recruiting in NCT06778187 and NCT06670222) is preferred; oral formulations may offer practical advantages for outpatient MDS management
Unclassified MDS subtype: The TxGNN rank 1 prediction (unclassified MDS, score 99.93%) has no dedicated clinical trials or literature; a prospective case series or registry study specifically in this subtype is needed to validate the model prediction
QTc monitoring protocol: Mandatory pre-treatment ECG and electrolyte management plan to be specified before any NZ patient receives ATO
Phase 3 evidence: Current evidence is predominantly Phase 1/2 and retrospective; a completed Phase 3 RCT in MDS (e.g., NCT03377725 was withdrawn) remains a critical gap before broader recommendation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.